International audienceThis paper focuses on the European Regulatory system which was settled both for opening the Single Market for products and ensuring the consumers' safety. It claims that the New Approach and Standardization, and the Global Approach to conformity assessment, which suppressed the last technical barriers to trade in Europe, realized the free movement of products by organizing progressively several orders of markets and regulation. Based on historical and institutional documents, on technical publications, and on interviews, this article relates how the European Commission and the Member States had alternatively recourse to markets and to regulations, at the three main levels of the New Approach Directives implementation. ...
This paper provides a comparison of European Union regulatory policy for pharmaceuticals and medical...
The generation of new medicinal products is both a contributor to global economic growth and a sourc...
'The EC harmonized market entry regulation for pharmaceuticals from the early sixties on, but it ach...
International audienceThis paper focuses on the European Regulatory system which was settled both fo...
International audienceIn the perspective of (political) governance, technical standardisation is oft...
This article provides an overview of the regulation of medical devices and drugs in the European Uni...
1 Abstract This thesis deals with the conflict between the interest in the free movement of medical ...
The medical product sector is characterised by a regulatory patchwork of European and national laws ...
Context Recent debates and events have brought into question the effectiveness of existing regulator...
The European Union's effort to create a single market involves the removal of trade barriers created...
A complex relationship exists among EU regulations, current national practices and rules, institutio...
It has been suggested that we are entering a new era in medical device regulation in Europe. This pa...
Part I of this thesis will describe the regulation of medical devices in the EEC. Before coming to t...
"The EC harmonized market entry regulation for pharmaceuticals from the early sixties on, but it ach...
In 2013, the CJEU ruled on the ‘Lyocentre’ case touching upon an important and contemporary issue in...
This paper provides a comparison of European Union regulatory policy for pharmaceuticals and medical...
The generation of new medicinal products is both a contributor to global economic growth and a sourc...
'The EC harmonized market entry regulation for pharmaceuticals from the early sixties on, but it ach...
International audienceThis paper focuses on the European Regulatory system which was settled both fo...
International audienceIn the perspective of (political) governance, technical standardisation is oft...
This article provides an overview of the regulation of medical devices and drugs in the European Uni...
1 Abstract This thesis deals with the conflict between the interest in the free movement of medical ...
The medical product sector is characterised by a regulatory patchwork of European and national laws ...
Context Recent debates and events have brought into question the effectiveness of existing regulator...
The European Union's effort to create a single market involves the removal of trade barriers created...
A complex relationship exists among EU regulations, current national practices and rules, institutio...
It has been suggested that we are entering a new era in medical device regulation in Europe. This pa...
Part I of this thesis will describe the regulation of medical devices in the EEC. Before coming to t...
"The EC harmonized market entry regulation for pharmaceuticals from the early sixties on, but it ach...
In 2013, the CJEU ruled on the ‘Lyocentre’ case touching upon an important and contemporary issue in...
This paper provides a comparison of European Union regulatory policy for pharmaceuticals and medical...
The generation of new medicinal products is both a contributor to global economic growth and a sourc...
'The EC harmonized market entry regulation for pharmaceuticals from the early sixties on, but it ach...